NetworkNewsWire Editorial Coverage:
Licensed cannabis producers in Canada are growing at remarkable
pace, swept forward by the country’s legalization of medicinal
marijuana in 2001 and impending legalization for recreational use
of the plant, set for July 1, 2018. Amid demand for cannabis in
various forms, oils are a significant contributor to the growth of
leading producers that are keeping an eye on evolving market trends
(http://nnw.fm/Xa32z). Key industry players such
as ABcann Global Corp. (OTCQB: ABCCF) (TSX.V: ABCN)
(ABCCF
Profile), Emblem Cannabis, Inc. (OTC: EMMBF) (TSXV: EMC),
Emerald Health Therapeutics, Inc. (OTCQX: EMHTF) (EMH: CC),
OrganiGram Holdings, Inc. (OTC: OGRMF) (CVE: OGI) and
Supreme Pharmaceuticals, Inc. (OTC: SPRWF) (TSXV:
FIRE) are leading the industry and adjusting their
strategies to include mounting consumer demand for oils.
ABcann Global
(OTCQB: ABCCF) (TSX.V: ABCN) is leveraging its
position as a globally licensed, cost efficient producer of premium
quality organic standardized medicinal cannabis to expand its
product line to include cannabis oils. As one of Canada’s first
licensed cannabis producers, ABcann is significantly ahead of the
curve when it comes to production capacities. The company’s
licensed and fully operational Vanluven Facility produces 1,000 kg
annually. Construction on the company’s Kimmett facility, an
industry-leading, purpose-built, world class style facility, is
under contract with another 65 acres under full Abcann ownership
for future expansion plans. As noted in its corporate presentation
(http://nnw.fm/W6rbx), ABcann’s yield per square
foot is 100 percent over the industry average.
Pivoting off its deep roots in pharmaceutical-grade cannabis,
ABcann’s wholly owned ABcann Medicinals, Inc. subsidiary in August
launched CBD-Med, one of Canada’s highest legal CBD:THC
(cannabidol:tetrahydrocannabinol) ratio products available on the
market (http://nnw.fm/sYv7g), under Health Canada
regulations.
The launch of CBD-Med is on par with ABcann’s broader strategy
to diversify its product line and capture its share of demand for
cannabis oils. Products that ABcann will have available for
patients are expected to include a 1-1 THC/CBD drop, a high THC
dropper and a high CBD dropper.
“The development of these products is in line with ABcann’s
corporate strategy as a premium product provider of organic,
pesticide free cannabis,” ABcann’s executive chairman stated in the
press release. “As the Company continues to scale production
capacity, our product line will expand as we strive to increase
shareholder value through capturing a larger market share of the
current global medical markets.”
CBD-Med’s high CBD content is a vital differentiating factor.
Although the virtues of THC have been loudly sung, many patients
exhibit adverse reactions, such as short-term memory impairment,
dysphoria (feeling uneasy for no apparent reason), increased levels
of anxiety and even panic attacks to the cannabinoid. On the other
hand, CBD is devoid of such side effects and, moreover, appears to
mitigate the injurious effects of THC when taken in conjunction
with it.
More than half (54%) the cannabis strains on the Canadian market
have a high THC-CBD ratio, with THC over 15% and CBD less than 1%.
Many others (29%) have less THC but negligible amounts of CBD, with
THC less than 15% and CBD below 1%. Only 14% of strains have both
THC and CBD levels that exceed 5%. And just 3% of strains have less
than 1% THC and more than 9% CBD, a highly prized category in which
CBD-Med can be found.
Emblem Cannabis, Inc. (OTC: EMMBF) (TSXV: EMC)
is also strategizing for its share of the market. Earlier this
month the company was granted a license to sell cannabis oils
(http://nnw.fm/0rdcB). Late last year, Emblem
was granted a supplemental license for the production of cannabis
extracts. John Stewart, President of Emblem’s Pharmaceutical
Division has emphasized the importance of this license to the
company’s plan to provide high quality, differentiated cannabis
products, in a variety of formats. Emblem plans to offer a
selection of cannabis oils, including those from CBD dominant
strains, THC dominant strains and strains with both CBD and THC
content. The company believes cannabis oils and related
formulations provide a level of consistency and dosage accuracy
that cannot be achieved with dried flower. Such products also
provide a method of consumption that many consumers find to be
substantially more precise and convenient.
Meanwhile, Emerald Health Therapeutics, Inc. (OTCQX:
EMHTF) (EMH: CC), through its Emerald Health Botanicals
subsidiary, as a licensed producer is already offering eight oils
with varying levels of THC, THCA, CBD, and THC to CBD ratios. The
product line includes the company’s recently launched CBD-25 and
CBD-50 medical cannabis oils containing approximately 25 milligrams
and 50 mg of CBD per milliliter (http://nnw.fm/mSfc3). The company believes that CBD-50
will provide a unique treatment option to doctors and patients
seeking high CBD potency with minimal THC. Its management is of the
opinion that CBD-50 contains the highest amount of CBD per
milliliter on the ACMPR market today. Emerald Health Botanicals is
now licensed to produce and sell both dried medical cannabis flower
and medical cannabis oil in Canada. The subsidiary currently
operates an indoor facility in Victoria, BC, and is making progress
on expansion plans for a 32-acre property in Metro Vancouver and a
joint venture with Village Farms that utilizes a 25-acre existing
greenhouse complex in Delta, BC.
Moncton, New Brunswick-based OrganiGram Holdings, Inc.
(OTC: OGRMF) (CVE: OGI) in June received an upgrade to its
licensed producer status (http://nnw.fm/47QlM), allowing both the production and
sale of cannabis oil extracts, as well as the company’s current
dried medical cannabis products. Quickly acting on that approval,
OrganiGram released Shubie, a pure CBD edible oil that expands its
range of cannabis oil offerings. Shubie is an ethanol-extracted
cannabis oil formulated in an organic sunflower oil base (http://nnw.fm/RTd4Y). This 50ml formulation boasts
23.7 mg/ml CBD and 1.39 mg/ml THC. Like the other oils in the
OrganiGram line up, Shubie was named for an iconic Atlantic
Canadian waterway, the Shubenacadie River.
Supreme Pharmaceuticals’ (OTC: SPRWF) (TSXV:
FIRE) wholly owned 7ACRES subsidiary recently received
approval from Health Canada to begin cultivation at its 30,000
square-foot flowering rooms at the company's hybrid grow facility.
The additional flowering rooms increases the size of 7ACRES'
flowering facility to 40,000 square feet. 7ACRES, and thus Supreme,
also has its footing in oils via a retail partnership with Aurora
Cannabis (TSX: ACB) (OTC: ACBFF). In its fourth-quarter financial
results, Aurora said sales of dried medical cannabis and cannabis
oils contributed $5.6 million to revenues, of which $0.4 million
(7.1%) was generated in Germany and $5.2 million in Canada
(http://nnw.fm/MOgY2).
Adoption of cannabis oil continues to increase as a preferred
alternative to cannabinoid consumption, providing cannabis
cultivators with an unprecedented market opportunity paced by
rising consumer demand.
For more information on ABcann Global please visit: ABcann Global
(TSX.V: ABCN) (OTCQB: ABCCF)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com